Search results
Found 20333 matches for
Established to test a range of potential treatments for COVID-19, the RECOVERY trial has included a comparison of colchicine, an anti-inflammatory drug that is commonly used to treat gout, vs. usual care alone. There has been no convincing evidence of the effect of colchicine on clinical outcomes in patients admitted to hospital with COVID-19, and recruitment to the colchicine arm of the RECOVERY trial has now closed. Recruitment to all other treatment arms – aspirin, baricitinib, Regeneron’s antibody cocktail, and dimethyl fumarate – continues as planned.
Direk Limmathurotsakul
Research Scientists
Direk Limmathurotsakul - Professor of Infectious Disease Epidemiology
Susanna Dunachie
Principal Investigators Research Scientists
Susanna Dunachie - Professor of Infectious Diseases
Trudie Lang
Principal Investigators Research Scientists
Trudie Lang - Professor of Global Health Research
Paul Newton
Principal Investigators Research Scientists
Paul Newton - Professor of Tropical Medicine
Thuong Thuong Nguyen
Principal Investigators Research Scientists
Thuong Thuong Nguyen - Associate Professor
Wirichada Pan-ngum
MSc IHTM Lecturers MSc MGH Lecturers Research Scientists
Wirichada Pan-ngum - Associate Professor
Anthony Scott
Principal Investigators Research Scientists
Anthony Scott - Visiting Professor of Vaccinology
Joel Tarning
MSc MGH Lecturers Principal Investigators Research Scientists
Joel Tarning - Professor of Clinical Pharmacology
Chris Paton
Principal Investigators Research Scientists
Chris Paton - Head of the Global Health Informatics Group
Brian Angus
MSc IHTM Lecturers MSc IHTM steering committee Principal Investigators Research Scientists
BSc, MBChB, DTM&H, FRCP, MD, FFTM Brian Angus - Professor and Reader in Infectious Diseases